ReviewMolecular oncology2019
German Cancer Consortium (DKTK) - A national consortium for translational cancer research.
Review in Molecular oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Mainzelliste: Ten years of pseudonymization, record linkage, and informed consent management.Patterns (New York, N.Y.) · 2026Article
- Describing the Core Attributes and Impact of Comprehensive Cancer Centers Internationally: A Chronological Scoping Review.Cancers · 2025Review
- Harmonization and standardization of personalized oncology care within the German network for personalized medicine (DNPM): methods of a controlled observational study employing an adapted stepped-wedge design.Frontiers in health services · 2025Article
- Advancing precision oncology with AI-powered genomic analysis.Frontiers in pharmacology · 2025Review
- The Journey to a FAIR CORE DATA SET for Diabetes Research in Germany.Scientific data · 2024Article
- Comparative analysis of integrative classification methods for multi-omics data.Briefings in bioinformatics · 2024Article
- The German Network for Personalized Medicine to enhance patient care and translational research.Nature medicine · 2023Article
- Profile of the multicenter cohort of the German Cancer Consortium's Clinical Communication Platform.European journal of epidemiology · 2023Article
- Record linkage based patient intersection cardinality for rare disease studies using Mainzelliste and secure multi-party computation.Journal of translational medicine · 2022Article
- The Architecture of a Feasibility Query Portal for Distributed COVID-19 Fast Healthcare Interoperability Resources (FHIR) Patient Data Repositories: Design and Implementation Study.JMIR medical informatics · 2022Article
- Global mapping of cancers: The Cancer Genome Atlas and beyond.Molecular oncology · 2021Review
- The Porto European Cancer Research Summit 2021.Molecular oncology · 2021Article
- Virotherapy in Germany-Recent Activities in Virus Engineering, Preclinical Development, and Clinical Studies.Viruses · 2021Review
- Joint Imaging Platform for Federated Clinical Data Analytics.JCO clinical cancer informatics · 2020Article
- Single-center versus multi-center data sets for molecular prognostic modeling: a simulation study.Radiation oncology (London, England) · 2020Article
- Benefits and challenges of Big Data in healthcare: an overview of the European initiatives.European journal of public health · 2019Review
- Boosting the social impact of innovative cancer research - towards a mission-oriented approach to cancer.Molecular oncology · 2019Article
- Translational cancer research - a coherent cancer research continuum.Molecular oncology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The German Cancer Consortium ('Deutsches Konsortium für Translationale Krebsforschung', DKTK) is a long-term cancer consortium, bringing together the German Cancer Research Center (DKFZ), Germany's largest life science research center, and the leading University Medical Center-based Comprehensive Cancer Centers (CCCs) at seven sites across Germany. DKTK was founded in 2012 following international peer review and has positioned itself since then as the leading network for translational cancer research in Germany. DKTK is long term funded by the German Ministry of Research and Education and the federal states of each DKTK partner site. DKTK acts at the interface between basic and clinical cancer research, one major focus being to generate suitable multisite cooperation structures and provide the basis for including higher numbers of patients and facilitate effective collaborative forward and reverse translational cancer research. The consortium addresses areas of high scientific and medical relevance and develops critical infrastructures, for example, for omics technologies, clinical and research big data exchange and analysis, imaging, and clinical grade drug manufacturing. Moreover, DKTK provides a very attractive environment for interdisciplinary and interinstitutional training and career development for clinician and medical scientists.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.